Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 256-262

  Müller, Karin ^a   Aichele, Simon ^a   Herkommer, Mario ^a   Bigalke, Boris ^a   Stellos, Konstantinos ^a   Htun, Patrik ^a   Fateh Moghadam, Suzanne ^a   May, Andreas E ^a   Flather, Marcus ^b   Gawaz, Meinrad ^a   Geisler, T ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Antiplatelet drug responsiveness; Aspirin; Clopidogrel; CRP; Inflammation; PCI

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON; ASPIRIN; BLOOD PLATELETS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INFLAMMATION; MALE; PILOT PROJECTS; PLATELET ACTIVATION; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77958466789     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.07.023     Document Type: Article

References (44)

1. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115(12):3378-3384.
2. May A.E., Kälsch T., Massberg S., et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002, 106(16):2111-2117.
3. Gawaz M., Neumann F.J., Dickfeld T., et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998, 98(12):1164-1171.
4. Viedt C., Vogel J., Athanasiou T., et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol 2002, 22(6):914-920.
5. Von Hundelshausen P., Koenen R.R., Sack M., et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005, 105(3):924-930.
6. Zhang Y., Wahl L.M. Synergistic enhancement of cytokine-induced human monocyte matrix metalloproteinase-1 by C-reactive protein and oxidized LDL through differential regulation of monocyte chemotactic protein-1 and prostaglandin E2. J Leukoc Biol 2006, 79:105-113.
7. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
8. Zairis M.N., Ambrose J.A., Manousakis S.J., et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the longterm prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002, 40:1375-1382.
9. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001, 104:992-997.
10. Buffon A., Liuzzo G., Biasucci L.M., et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999, 34:1512-1521.
11. Palmerini T., Marzocchi A., Marrozzini C., et al. Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation 2005, 112:2332-2338.
12. Gach O., Legrand V., Biessaux Y., et al. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol 2007, 99:31-35.
13. Park D.W., Yun S.C., Lee J.Y., et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009, 120(20):1987-1995.
14. Geisler T., Langer H., Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006, 27(20):2420-2425.
15. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006, 48(9):1742-1750.
16. Geisler T., Grass D., Bigalke B., et al. The PREDICT (Residual Platelet Aggregation after Deployment of Intracoronary Stent)-Score. J Thromb Haemostasis 2008, 6(1):54-61.
17. Geisler T., Schaeffeler E., Dippon J., et al. Cytochrome P450 2C19 and non-genetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008, 9(9):1251-1259.
18. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53(10):849-856.
19. Gori A.M., Cesari F., Marcucci R., et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009, 202(1):255-262.
20. Velik-Salchner C., Maier S., Innerhofer P., et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008, 107(6):1798-1806.
21. Sibbing D., Busch G., Braun S., et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008, 29:1504-1509.
22. Siller-Matula J.M., Gouya G., Wolzt M., Jilma B. Cross validation of the multiple electrode aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009, 102(2):397-403.
23. Müller I., Besta F., Schulz C., et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003, 89(5):783-787.
24. Gurbel P.A., Bliden K.P., Hayes K.M., et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005, 45:1392-1396.
25. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(June (23)):2908-2913.
26. Müller I., Seyfarth M., Rüdiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85(1):92-93.
27. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111(20):2560-2564.
28. Gawaz M., Ruf A., Neumann F.J., et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998, 80(6):994-1001.
29. Neumann F.J., Hochholzer W., Pogatsa-Murray G., et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001, 37(5):1323-1328.
30. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115(17):2344-2351.
31. Albert C.M., Ma J., Rifai N., Stampfer M.J., Ridker P.M. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002, 105:2595-2599.
32. Stuveling E.M., Hillege H.L., Bakker S.J., et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003, 63(2):654-661.
33. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001, 32:2575-2579.
34. Frossard M., Fuchs I., Leitner J.M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004, 110:1392-1397.
35. Geisler T., Kapp M., Göhring-Frischholz K., et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008, 94(6):743-747.
36. Harding S.A., Sarma J., Din J.N., et al. Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 2006, 92(9):1335-1337.
37. Cavusoglu E., Eng C., Chopra V., et al. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 2007, 27(4):929-935.
38. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354-362.
39. Paruchuri S., Tashimo H., Feng C., et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. Exp Med 2009, 206(11):2543-2555.
40. Diehl P., Olivier C., Halscheid C., et al. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y(12) expressing leukocytes. Basic Res Cardiol 2010, 105(3):379-387.
41. Dosh K., Berger P.B., Marso S., et al. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv 2009, 2(6):503-512.
42. Chew D.P., Bhatt D.L., Robbins M.A., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001, 88(6):672-674.
43. Xiao Z., Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004, 43(11):1982-1988.
44. Saltzman A.J., Mehran R., Hooper W.C., et al. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. J Invasive Cardiol 2010, 22(1):2-6.